Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 518 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07863999RecruitingPhase 3
Immunotherapy before surgery for stage II-III lung cancer
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
Shanghai, ChinaAges 18 years+ - NCT07074470Recruiting
New drug combo for relapsed brain lymphoma
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
Suzhou, JiangsuAges 18–75 - NCT06194656RecruitingPhase 2
Trial of SIBP-03 for advanced head and neck cancer
This trial tests a new drug called SIBP-03 for people with head and neck squamous cell carcinoma that has come back or spread. It is for those whose cancer has worsened after prior immunotherapy and platinum chemotherapy, and who have no option for curative local treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07845058RecruitingPhase 2
Combination therapy for a functional cure of chronic hepatitis B
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07729956RecruitingPhase 3
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07689578RecruitingPhase 4
Testing a new immunotherapy for chronic kidney transplant rejection
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Chengdu, SichuanAges 18 years+ - NCT06796517Recruiting
Immunotherapy for relapsed or refractory lymphoma
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
SeoulAges 19–74 - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06195228RecruitingPhase 4
Real-world study of genetic types in advanced thyroid cancer
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
Fuzhou, FujianAges Any age - NCT06537908Recruiting
Check if a new drug combo works for advanced liver cancer
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
ShanghaiAges 18–90 - NCT06484153RecruitingPhase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Wuhan, HubeiAges 18–75 - NCT06393361RecruitingPhase 2
Combination therapy for relapsed Hodgkin lymphoma without transplant
This trial tests a combination of two oral targeted drugs (chidamide and decitabine) plus an immunotherapy drug (anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has not responded to at least two prior treatments and who cannot or choose not to have a stem cell transplant. The goal is to see if this three-drug combination can shrink tumors and help control the disease.
BeijingAges 18–75 - NCT06069830Recruiting
PET scan and EBV test guided treatment for nasal NK/T cell lymphoma
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Lexington, KentuckyAges 18 years+ - NCT05342792RecruitingPhase 3
Chemo tablets with or without an immune therapy after cancer treatment
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
Guangzhou, GuangdongAges 18–65 - NCT05447169Recruiting
Testing blood and DNA checks for nasopharyngeal cancer risk
This study tests an Epstein-Barr virus (EBV) blood antibody and an EBV DNA test to help screen people at higher risk for nasopharyngeal cancer. It may find signs earlier in certain families where cancer runs.
Guangzhou, GuangdongAges 30–62 - NCT05681975Recruiting
Test whether antibodies relate to food reaction symptoms
This study looks at adults who have symptoms they believe are caused by reactions to foods. Researchers will test immune blood markers (antibodies) to better understand what may be driving these symptoms and whether that information could help people in the future.
MadridAges 18–80 - NCT05631886RecruitingPhase 1
Testing a cancer vaccine plus immune therapy for hard tumors
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Beijing, Beijing MunicipalityAges 18–75 - NCT06203249Recruiting
Exploring lung health and immune system in a rare muscle disease
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
Beijing, Beijing MunicipalityAges 18–100 - NCT07860047RecruitingPhase 2
Peptide vaccine with antibody therapy for prostate cancer
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
Heidelberg, Baden-WurttembergAges 18–80
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 518 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.